修改为:et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplifed (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. J Clin Oncol 2023...
修改为:et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplifed (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. J Clin Oncol 2023; 41:3501. 2024 年第 1 版直肠癌 NCCN 指南相较...
This selection from the NCCN Guidelines for Rectal Cancer focuses on management of malignant polyps and resectable nonmetastatic rectal cancer because important updates have been made to these guidelines. These recent updates include redrawing the algorithms for stage II and III disease to reflect new ...
2.NCCN. Clinical Practice Guidelines in Oncology. Colon cancer, version 5.2024. Accessed November 18, 2024. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf 3.NCCN. Clinical Practice Guidelines in Oncology. ...
In its updated guidelines for colon cancer1and for rectal cancer2, NCCN now includes ctDNA as a high risk factor for recurrence in the adjuvant setting, recognizing its prognostic value. This represents a significant step forward as it’s the first time the committee has fo...
latest research progress in molecular detection, immunotherapy, targeted therapy, neoadjuvant therapy and disease surveillance. This article analyzed the key updates of the 2024 V1/V2 NCCN guidelines, aiming to provide a more accurate reference for clinical rectal cancer diagnosis and treatment practice....
本文就2024年V4版《NCCN结肠癌临床实践指南》(以下简称《指南》)中更新要点做简要解读,主要从生物标志物检测、转移性结肠癌(metastatic colon cancer,mCC)治疗以及生存预后等方面进行阐述。总体上,《指南》的更新为结肠癌的综合管理提供了更科学和全面的指导,强调了全科医生在结肠癌筛查、诊断和预后中的重要性。 1...
4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。 5. 装配图网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022;386(25):2363-2376. doi:10.1056/NEJMoa2201445 15. NCCN. Clinical practice guidelines in oncology. Rectal cancers, version 1.2023. Accessed April 5, 2023. https://bit.ly/2IvzwBF...
Thomas Flaig, MD, discusses recent updates seen in the bladder cancer space and how they have led to changes to the NCCN guidelines. Thomas Flaig, MD, vice chancellor of research for the University of Colorado Denver, member, University of Colorado Cancer Center, and the University of Color...